Cell and Gene Therapy
Refine Search
Biotechnology
Bayer’s wholly-owned subsidiary BlueRock Therapeutics has established a new site for cell therapy innovation on the pharma major’s campus in Berlin, Germany. 8 June 2022
Biotechnology
Swiss pharmaceutical company Bachem has partnered with Eli Lilly to advance the development of oligonucleotide-based drug substances. 7 June 2022
Biotechnology
Kite, a subsidiary of US biotech major Gilead Sciences, over the weekend announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). 6 June 2022
Biotechnology
Biotech funder and incubator Flagship Pioneering and Tessera Therapeutics, a biotechnology company pioneering GENE WRITING technology backed by Flagship, today announced that Michael Severino has joined Tessera as chief executive. 3 June 2022
Biotechnology
Immatics Biotechnologies saw its American-traded shares rise just a modest 3.2% to $7.79 this morning, despite signing a multi-billion-dollar deal, albeit heavily back-loaded. 2 June 2022
Biotechnology
German biotech Evotec today announced the signing of a definitive agreement to acquire 100% of the capital of Rigenerand Srl, an Italian cell technology company. 30 May 2022
Biotechnology
The US Food and Drug Administration has granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy, said Swiss pharma giant Novartis. 28 May 2022
Pharmaceutical
Indiana, USA-based drugmaker Eli Lilly is making a major investment in its home state, with a $2.1 billion project to expand its manufacturing footprint. 26 May 2022
Biotechnology
Antios Therapeutics has been given the cold shoulder by erstwhile development partner Assembly Biosciences, after a clinical hold was placed on its hepatitis B program. 26 May 2022
Biotechnology
The US Food and Drug Administration has accepted for priority review the Biologics License Application (BLA) submitted by CSL Behring, a subsidiary of Australia’s CSL Limited, for etranacogene dezaparvovec, an investigational gene therapy for the treatment of adults with hemophilia B. 25 May 2022
Biotechnology
US ultra-rare disease specialist Ultragenyx Pharmaceutical and gene and cell therapy company Abeona Therapeutics have announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA). 18 May 2022
Biotechnology
Shares in CRISPR genome-editing biopharma company Caribou Biosciences were worth 37% more at mid-morning Friday than they were at Wednesday’s close. 13 May 2022
Biotechnology
Belgium’s cell therapy developer Bone Therapeutics (Euronext: BOTHE) today announced it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic. 12 May 2022
Biotechnology
Gene therapy company Opus Genetics, which is developing treatments for inherited retinal diseases, today announced the appointment of Jennifer Hunt as chief development officer. 11 May 2022
Biotechnology
The year 2021 was important for the development of new gene-, cell- and tissue-based therapies, and the Alliance for Regenerative Medicines (ARM) says this year will be another year of growth and progress for these advanced therapies, according to its 2021 annual report. 9 May 2022
Biotechnology
An Expert View from Mark Brewer, research director, Life Sciences, finnCap. 6 May 2022
Biotechnology
Swiss pharma giant Novartis says that the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. 5 May 2022
Biotechnology
A clinical hold on Phase I/II research into stem cell therapy VX-880 has left executives at Vertex Pharmaceuticals scratching their heads. 3 May 2022
Biotechnology
An Expert View from Neelam Patel, chief executive of MedCity, a not-for-profit that serves as the life sciences cluster organization for London. 2 May 2022
Pharmaceutical
Following a previously delayed decision, the US Food and Drug Administration has now approved Camzyos (mavacamten, 2.5mg, 5mg, 10mg, 15mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. 29 April 2022
Biotechnology
US clinical-stage biotech Vyriad has entered into a strategic collaboration with Swiss pharma giant Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. 21 November 2024
Biotechnology
Australia’s CSL Limited plans to shut down its Californian R&D facility focused on cell and gene therapies by January 2025, signaling a shift away from ex vivo lentiviral-based technology. 19 November 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain. 14 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Biotechnology
Sarepta Therapeutics has announced it will cease development of SRP-5051, an experimental drug for Duchenne muscular dystrophy, citing safety issues, feedback from the Food and Drug Administration, and the shifting Duchenne treatment landscape. 11 November 2024
Biotechnology
Asklepios BioPharmaceutical (AskBio) today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug designation from the US Food and Drug Administration (FDA) for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). 7 November 2024
Biotechnology
The global market for Duchenne muscular dystrophy (DMD) therapeutics is projected to grow by $4.4 billion between 2024 and 2028, fueled by artificial intelligence and strong demand for new treatments. 7 November 2024
Biotechnology
Ring Therapeutics, a biotech based in Massachusetts, USA, has announced strategic partnerships with Singapore’s Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI). 5 November 2024
Biotechnology
The global DNA synthesis market will grow by $6.5 billion over the next five years, according to a new report from Technavio. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Intellia Therapeutics has announced Phase II results for its CRISPR-based therapy, NTLA-2002, aimed at providing a one-time treatment for hereditary angioedema (HAE). 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Editas Medicine has announced plans to seek a partner or buyer for its lead CRISPR program, reni-cel, as the company continues to shift its strategy. 23 October 2024
Biotechnology
Shares in Sangamo Therapeutics surged around 40% on Tuesday, following the announcement that the US Food and Drug Administration has granted the company a faster path to approval for its gene therapy ST-920 (isaralgagene civaparvovec) for Fabry disease. 23 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze